Rene K Olesen

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Timothy Iveson, Rachel Kerr, Mark Saunders et al. · The Lancet Oncology · 2018 · 183 citations · Full text

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

Timothy Iveson, Kathleen Boyd, Rachel Kerr et al. · Health Technology Assessment · 2019 · 34 citations · Full text

Texture in the monitoring of regorafenib therapy in patients with colorectal liver metastases

Iben Rahbek Andersen, Kennet Thorup, Michael Brun Andersen et al. · Acta Radiologica · 2019 · 33 citations

Sorafenib in Advanced Hepatocellular Carcinoma: A Nationwide Retrospective Study of Efficacy and Tolerability

Anne Helene Køstner, Morten Mau‐Sørensen, Rene K Olesen et al. · The Scientific World JOURNAL · 2013 · 29 citations · Full text

NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer

Lars Henrik Jensen, Rene K Olesen, L. Noergaard Petersen et al. · Cancers · 2019 · 25 citations · Full text